Pre-made Parsatuzumab benchmark antibody ( Whole mAb, anti-EGFL7 therapeutic antibody, Anti-NEU1/VE-STATIN/ZNEU1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Parsatuzumab biosimilar, Whole mAb, Anti-EGFL7 Antibody: Anti-NEU1/VE-STATIN/ZNEU1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-428-1mg	1mg	3090
GMP-Bios-ab-428-10mg	10mg	Inquiry
GMP-Bios-ab-428-100mg	100mg	Inquiry
GMP-Bios-ab-428-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Parsatuzumab biosimilar, Whole mAb, Anti-EGFL7 Antibody: Anti-NEU1/VE-STATIN/ZNEU1 therapeutic antibody
INN Name	Parsatuzumab
Target	EGFL7
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Chugai Pharmaceutical;Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Colorectal cancer;Non-small cell lung cancer;Solid tumours
Development Tech	na